Enlisting supramolecular hydrogels to fight coronavirus
Most vaccines in use today were developed using techniques invented more than 100 years ago. The design of vaccines that have ease of distribution and reduced cost remains a major technological challenge. In view of the COVID-19 pandemic, there is growing pressure to develop new technologies to address severe infectious diseases. The EU-funded HYPOVACC project will develop a novel biocompatible, injectable and scalable vaccine technology based on supramolecular hydrogel-containing polymersomes to enable controlled local vaccine exposure for durable and broadly protective immune response against the coronavirus. The project research will cover new vaccine delivery technologies and recently developed immunological assays.
Fields of science
Call for proposal
See other projects for this call